OPX 212

Drug Profile

OPX 212

Alternative Names: OPX-212

Latest Information Update: 14 Nov 2015

Price : $50

At a glance

  • Originator Opexa Therapeutics
  • Class Anti-inflammatories; Cell therapies; Eye disorder therapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neuromyelitis optica

Most Recent Events

  • 10 Nov 2015 Efficacy data from a preclinical trial in Neuromyelitis optica released by Opexa
  • 01 Sep 2015 Opexa plans a phase I/II trial for Neuromyelitis optica
  • 09 Jun 2015 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top